First in-human milestone for MicroBlate™ Flex

Creo Medical Group PLC

23 May 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

First in-human milestone reached for MicroBlate™ Flex as part of Lung Tissue ablation clinical study

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that, further to the update of 31 March 2023, the first in-human use of the Company's MicroBlate Flex device for the microwave (MW) ablation of soft tissue lung lesions was successfully completed at Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust, by Professor Pallav L Shah.

Creo's MicroBlate Flex device is a new soft tissue ablation device which is designed with the aim of being able to ablate nodules and tumors in several tissue types using the highest frequency MW energy for tumour ablation.

The aforementioned procedure forms part of a multi-site clinical trial, with all patients having regular follow-up assessments post-procedure to monitor their progress. The Study¹ is the first of a number of planned studies regarding the Company's suite of ablation devices during 2023 and beyond.

Craig Gulliford, Chief Executive Officer of Creo, commented: "This is another landmark moment for Creo Medical. Lung cancer has the second highest incidence of the top 5 cancers and one of the lowest 5-year survival rates. Unlike most other cancers; there are no significant, accurate screening programmes in place for lung cancer but with screening, diagnosis and navigation technology advancing dramatically over recent years, we are set to see that change.

"The goal of screening is to find the disease early when the tumours are small. However, currently the treatment options for these early-stage lesions are inappropriately invasive, typically involving chemotherapy, radiation therapy, surgery or a combination thereof.

"MicroBlate Flex has been designed for a range of different applications, including the capability of operating with these new lung cancer diagnosis and navigation technologies, and is ideal for the targeted ablation of pre-cancerous and potentially cancerous lesions in the lung and in other soft tissue. Like with all our products now in clinical practice in the gastroenterology market, we hope that our technology will enable clinicians to significantly impact on the improvement of Cancer outcomes.

"The whole team at Creo are delighted that this clinical program has now started. The first enrolment and MicroBlate Flex's first procedure safely completed is an important milestone in our goal to use advanced energy to transform lives."

Professor Shah added: "The ablate device is another tool in our armoury for treating early lung cancers or metastatic tumours in the lung. It provides an alternative approach when surgery is not possible and may have the potential to create a very controlled ablation minimising any additional lung damage. The current trial should help evaluate its safety and role in thoracic cancers."

¹ Bronchoscopic Microwave Ablation of Lung Tissue - Full Text View - ClinicalTrials.gov

Enquiries:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities plc	[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Numis Securities Limited (Joint Broker) Freddie Barnfield / James Black / Duncan Monteith	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen / Phillip Marriage	Mob: [phone]

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.  CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END